189559-85-1 Usage
General Description
Ethanone, 1-(1H-indazol-6-yl)- (9CI) is a specialized chemical often used in laboratory and research settings. Detailing its composition, it includes an indazole group, which is an organic compound containing a nitrogen atom, linked to the position 6 in its structure. The "Ethanone" designation reveals that it's a type of ketone, which indicates the possession of a carbonyl group. Furthermore, the "(9CI)" implies its classification under the Ninth Collective Index system. Although its specific uses may vary, it is primarily significant in the field of synthetic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 189559-85-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,9,5,5 and 9 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 189559-85:
(8*1)+(7*8)+(6*9)+(5*5)+(4*5)+(3*9)+(2*8)+(1*5)=211
211 % 10 = 1
So 189559-85-1 is a valid CAS Registry Number.
InChI:InChI=1/C9H8N2O/c1-6(12)7-2-3-8-5-10-11-9(8)4-7/h2-5H,1H3,(H,10,11)
189559-85-1Relevant articles and documents
HISTONE DEMETHYLASE INHIBITORS
-
Paragraph 00302; 00303, (2014/06/24)
Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.
BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS AURORA KINASE INHIBITORS
-
Page/Page column 94-95, (2010/11/28)
The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.
